SCHEMBL19975291

SCHEMBL19975291

CC(NC(=O)C1CC(F)(F)C1)C(O)C(=O)NCC1CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.38
ATM Q13315 2/20 0.34
TDP1 Q9NUW8 2/20 0.33
EPHX1 P07099 1/20 0.33
MEN1 O00255 3/20 0.33
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2D6 P10635 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
TSHR P16473 2/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
TP53 P04637 1/20 0.32
GPR88 Q9GZN0 1/20 0.31
KDM1A O60341 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975163 0.88 KMT2A (0.38) KMT2AATMTDP1EPHX1MEN1
SCHEMBL19975563 0.83 EPHX1 (0.53) KMT2AEPHX1CYP3A4TSHRALDH1A1
SCHEMBL21183567 0.77 KMT2A (0.36) KMT2AATMTDP1EPHX1MEN1
SCHEMBL19975390 0.75 TDP1 (0.42) KMT2ATDP1EPHX1MEN1TSHR
SCHEMBL19975518 0.74 KMT2A (0.44) KMT2AATMTDP1MEN1TSHR
SCHEMBL21176307 0.74 EPHX2 (0.40) KMT2ATDP1CYP3A4KDM1A
SCHEMBL24571812 0.72 TAS1R3 (0.34) KMT2AMEN1ALDH1A1
SCHEMBL24567723 0.72 TAS1R3 (0.34) KMT2AMEN1ALDH1A1
SCHEMBL19975361 0.72 EPHX1 (0.40) KMT2AEPHX1MEN1TSHRALDH1A1
SCHEMBL19975135 0.70 CTSL (0.52) KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885ATM 4579/4885TDP1 1016/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C KMT2A 4177/4885ATM 4543/4885TDP1 911/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C KMT2A 4031/4885ATM 4579/4885TDP1 1016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.